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BaP1 was isolated from B. asper venom as previously described1, 2 .
 
Solvents and reagents 
were purchased from commercial suppliers and were used without further purification. The 
compounds ZINC06812429 (A1) and ZINC08767570 (A2) were purchased from MolPort 
(https://www.molport.com). 
 
In Silico Ligand preparation 
 
Our approach centered on identifying a series of compounds with functional groups that can 
coordinate with the Zn(II) (ZBG) and groups that interact with the subsite S1´ of the BaP1 
protein. Three virtual libraries were used to search for such compounds ZINC using the 
Drug-like physical property subsets in the .sdf file format at pH 6-8, the CHEMBL data base 
(CHEMBL_17, CHEMB_MMP) and PubChem. The first step was the database curation. 
Using Pipeline Pilot (BIOVIA/Accelrys Inc., San Diego, CA, USA), a workflow was 
designed as illustrated in Figure S1. 
 
 
To prepare the library, “Generate Conformation” protocol from Pipeline Pilot was applied. 
This protocol offers a selection of conformation and torsion search methods for creating 
diverse ligand conformations. Conformation search method was set to FAST.  
Figure S1. Pipeline Pilot workflow design for the curation of the combination virtual library (Zinc, 
PubChem, ChemBl and ChemBl with refine ligand for MMP). 
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Figure S2. Pipeline Pilot workflow of Virtual High Throughput Screening used in analysis of the ligand 
poses of the BaP1 inhibitors. 
In Silico Protein preparation  
BaP1 enzyme was downloaded from Protein Data Bank (PDB code: 2W14)3. BaP1’s 
structure was prepared by using “Prepare Protein” protocol available in Discovey Studio 
(DS) version 4.0 (BIOVIA/Accelrys Inc., San Diego, CA, USA). Default parameters were 
used.  
Pharmacophore  
Considering ligand-interacting BaP1 residues, a pharmacophore model was built applying 
“Interaction Generation” protocol implemented in DS 4.0 with default parameters. This 
protocol extracts pharmacophore queries from the Ludi interaction map created inside the 
active site sphere and assigns three main features namely HBA (Hydrogen Bond Acceptor), 
HBD (Hydrogen Bond Donor) and HY (Hydrophobic). The HBD feature that orients to the 
zinc(II) ion has been replaced by zinc feature using the option “Add Feature From 
Dictionary” under the pharmacophore tab in DS 4.0. The zinc feature in the present study was 
modified to detect the following functional groups: carboxyl, phosphate, imidazole, 1,2,3-
triazole, 1,2,4-triazole, tetrazole, thiadiazole, 1-hydroxy-2-oxo derivatives4. 
Virtual High-Throughput Screening  
Once prepared the ligand library and the target, the Virtual High Throughput Screening was 
carried on. The docking workflow was designed using Pipeline. This Workflow had a series 














Inhibition of proteolytic activity  
Inhibition of the proteolytic activity of the BaP1 was assessed using the azocasein as a 
substrate and as described elsewhere6, 7. The BaP1 was diluted in the reaction buffer, mixed 
with the inhibitor dissolved in dimethyl sulfoxide (DMSO) and this mixture was incubated 
for 30 min at 37 °C. Then, 100 μL of the azocasein solution was added and incubated for 90 
min at 37 °C. Finally, 200 μL of trichloroacetic acid (5% solution) were added to quench the 
reaction and the samples were centrifuged for 10 min at 4,000  g. 100 μL of the supernatant 
was mixed with an equal amount of 0.5 mol.L-1 of NaOH in H2O. The absorbance was 
recorded at 450 nm. The final concentration of BaP1 was 2 µmol.L-1. The half maximal 
inhibitory concentrations (IC50) as measures of the effectiveness of the two compounds (A1 
and A2) in inhibiting BaP17, 8 function were determined after incubating the BaP1 at 37 °C. 
during 30 min with different concentrations of A1 or A2 inhibitors, which varied from 0 to 
100 µmol.L-1, and then, the solution of the azocaisein was added and experiments continued 




The BaP1 CD spectra were obtained from 4 µmol.L-1 protein concentration in 25 mM.L-1 Tris 
buffer at pH = 8.0. The spectra were recorded from 200 to 260 nm with a Jasco J-720 
spectropolarimeter (JASCO International Co. Ltd., Tokyo, Japan). For 2D structure features 
assessment, temperature of 25 ºC was used. Also, 1 mm path length cell, average of 8 scan at 
a scan speed of 20 nm/min were used. For assessing the thermal stability of the BaP1, two 
protein samples were heated in range from 25 to 80 ºC with a ramp of 10 ºC/h, and the water 
bath (ThermoFisher) was used. 
 
Protein Fluorescence 
The relative intrinsic fluorescence of BaP1 free and with the inhibitors was monitored with a 
Varian (Varian, Palo Alto, USA) spectrofluorimeter. The protein sample and reaction 
mixtures (all volumes were 500 µL) were put into 1 cm path length quartz cuvette. We used 
as buffer 25 mM.L-1 Tris-HCl (pH 8.0). These were titrated with DMSO solution of 
inhibitors. These experiments were performed three-times for each inhibitor (A1 and A2) 
concentration. Fluorescence was measured between 300 and 500 nm after excitation at 
280 nm. The Stock-Volmer graphs were plot and Kd was determined applying a non-linear 
regression performed with Origin (OriginLab Corporation). 
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Virtual Screening Results 
 
Table S1 Structure and CDDOCKER ENERGY of 50 best-ranked compounds 



























































































































































Quantum Mechanical and Molecular Mechanical (QM/MM) Docking 
 
Although compounds A1 and A2 are structurally similar, their best-scored poses from the 
virtual screening campaign were dissimilar. That’s possibly due to CDOCKER’s lack of 
force field parameterization for metalloproteinases. In order to overcome this problem and 
shed some light on the possible binding modes of compounds A1 and A2, re-docking studies 
were performed using the protocol “CDOCKER with QM Charges” as implemented in 
Pipeline Pilot with default parameters. 
 
This protocol contains three main steps. First step consists of the initial placement of the 
ligand in the binding site using CDOCKER (MM) docking program, followed by a RMSD 
filter procedure to ensure that initial ligand poses (predicted binding modes) are diverse. In 
step two, ligand atomic charges are calculated for each pose by quantum mechanical methods 
(QM) in the presence of the enzyme. More specifically, QM charges calculation is performed 
using dmol3 with the PBE functional. Lastly, in the third step the ligand is re-docked with 
CDOCKER considering atomic ligand charges calculated previously. 
 
The best scored QM/MM docked pose for each compound were depicted in Figure 1. 






Figure S3. 2D-interaction diagram for compounds A1 and A2 plotted using LIGPLOT+9. 
Red arcs represent hydrophobic interactions. Hydrogen bonds, metal and charged 
interactions are indicated by green dashed lines. Ligands and enzyme amino acid residues 
are depicted in purple and orange, respectively. C, N, O and ZN atoms are colored in 
black, blue, red and green respectively. (A) A1 - ZINC06812429; (B) A2 - ZINC08767570. 
Π-stacking interactions are not depicted by LIGPLOT+, even though they do constitute 
an important interactive element among A1 ligand and enzyme. 
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